806 related articles for article (PubMed ID: 18334909)
1. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
Potkin SG; Litman RE; Torres R; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
[TBL] [Abstract][Full Text] [Related]
6. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
7. Iloperidone for the treatment of schizophrenia.
Marino J; Caballero J
Ann Pharmacother; 2010 May; 44(5):863-70. PubMed ID: 20388862
[TBL] [Abstract][Full Text] [Related]
8. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.
Cutler AJ; Kalali AH; Mattingly GW; Kunovac J; Meng X
CNS Spectr; 2013 Feb; 18(1):43-54. PubMed ID: 23312567
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
12. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
[TBL] [Abstract][Full Text] [Related]
14. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
15. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
[TBL] [Abstract][Full Text] [Related]
17. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
18. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
[TBL] [Abstract][Full Text] [Related]
19. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]